130 related articles for article (PubMed ID: 15604014)
1. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.
Beum PV; Kennedy AD; Li Y; Pawluczkowycz AW; Williams ME; Taylor RP
J Immunol Methods; 2004 Nov; 294(1-2):37-42. PubMed ID: 15604014
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of protein co-localization on B cells opsonized with rituximab and complement using the ImageStream multispectral imaging flow cytometer.
Beum PV; Lindorfer MA; Hall BE; George TC; Frost K; Morrissey PJ; Taylor RP
J Immunol Methods; 2006 Dec; 317(1-2):90-9. PubMed ID: 17067631
[TBL] [Abstract][Full Text] [Related]
3. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
[TBL] [Abstract][Full Text] [Related]
4. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
5. Covalent binding of C3b to monoclonal antibodies selectively up-regulates heavy chain epitope recognition by T cells.
Santoro L; Drouet C; Reboul A; Mach JP; Colomb MG
Eur J Immunol; 1994 Jul; 24(7):1620-6. PubMed ID: 8026522
[TBL] [Abstract][Full Text] [Related]
6. Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b.
DiLillo DJ; Pawluczkowycz AW; Peng W; Kennedy AD; Beum PV; Lindorfer MA; Taylor RP
Mol Immunol; 2006 Mar; 43(7):1010-9. PubMed ID: 15961157
[TBL] [Abstract][Full Text] [Related]
7. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
[TBL] [Abstract][Full Text] [Related]
8. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.
Peng W; Zhang X; Mohamed N; Inghirami G; Takeshita K; Pecora A; Nardone LL; Pincus SE; Casey LS; Spitalny GL
Cancer Immunol Immunother; 2005 Dec; 54(12):1172-9. PubMed ID: 15846490
[TBL] [Abstract][Full Text] [Related]
9. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.
Beum PV; Lindorfer MA; Beurskens F; Stukenberg PT; Lokhorst HM; Pawluczkowycz AW; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2008 Jul; 181(1):822-32. PubMed ID: 18566448
[TBL] [Abstract][Full Text] [Related]
10. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
[TBL] [Abstract][Full Text] [Related]
11. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
12. Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers.
Beum PV; Lindorfer MA; Peek EM; Stukenberg PT; de Weers M; Beurskens FJ; Parren PW; van de Winkel JG; Taylor RP
Eur J Immunol; 2011 Aug; 41(8):2436-46. PubMed ID: 21674476
[TBL] [Abstract][Full Text] [Related]
13. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of the B-cell marker CD20.
Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
[TBL] [Abstract][Full Text] [Related]
16. How naturally occurring anti-band 3 antibodies stimulate C3b deposition to senescent and oxidatively stressed red blood cells.
Lutz HU; Stammler P; Fasler S
Biomed Biochim Acta; 1990; 49(2-3):S224-9. PubMed ID: 2386510
[TBL] [Abstract][Full Text] [Related]
17. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
18. Amplification of the antibody response by C3b complexed to antigen through an ester link.
Villiers MB; Villiers CL; Laharie AM; Marche PN
J Immunol; 1999 Mar; 162(6):3647-52. PubMed ID: 10092826
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization.
Wu GD; He Y; Chai NN; Toyoda M; Dunn R; Kehry MR; Klein AS; Jordan SC
Transpl Immunol; 2008 Jul; 19(3-4):178-86. PubMed ID: 18595710
[TBL] [Abstract][Full Text] [Related]
20. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
